Advert - Martindale Pharma

For advertising Espranor oral lyophilisate (buprenorphine) (substitution therapy for opioid dependence) to the public and for making claims in material aimed at patients and health professionals which were, inter alia, prejudicial to patient safety, Martindale was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 7.2 - Providing misleading information
Clause 7.3 - Making misleading comparisons
Clause 7.4 - Making unsubstantiated claims
Clause 7.9 - Making claims that did not reflect the available evidence regarding possible adverse reactions
Clause 9.1 - Failing to maintain high standards
Clause 26.1 - Advertising a prescription only medicine to the public
Clause 26.2 - Providing unbalanced information and encouraging members of the public to ask for a specific prescription only medicine

Advert - May 2018